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mamfishe@iu.eduSummaryNeonatal severe hyperparathyroidism (NSHPT) is a rare disorder caused by inactivating calcium-sensing receptor (CASR)
mutations that result in life-threatening hypercalcemia and metabolic bone disease. Until recently, therapy has been surgical
parathyroidectomy. Three previous case reports have shown successful medical management of NSHPT with cinacalcet. Here
we present the detailed description of two unrelated patients with NSHPT due to heterozygous R185Q CASR mutations.
Patient 1 was diagnosed at 11 months of age and had developmental delays, dysphagia, bell-shaped chest, and periosteal
bone reactions. Patient 2 was diagnosed at 1 month of age and had failure to thrive, osteopenia, and multiple rib fractures.
Cinacalcet was initiated at 13 months of age in patient 1, and at 4 months of age in patient 2. We have successfully
normalized their parathyroid hormone and alkaline phosphatase levels. Despite the continuance of mild hypercalcemia
(11–12 mg/dl), both patients showed no hypercalcemic symptoms. Importantly, patient 1 had improved neurodevelopment
and patient 2 never experienced any developmental delays after starting cinacalcet. Neither experienced fractures after
starting cinacalcet. Both have been successfully managed long-term without any significant adverse events. These cases
expand the current literature of cinacalcet use in NSHPT to five successful reported cases. We propose that cinacalcet may be
considered as an option for treating the severe hypercalcemia and metabolic bone disease found in infants and children with
inactivating CASR disorders.Learning points:
† NSHPT due to mutations in the CASR gene occurs with hypercalcemia and metabolic bone disease, but not always
with severe critical illness in infancy.
† NSHPT should be considered in the differential diagnosis for a newborn with a bell-shaped chest, osteopenia, and
periosteal reactions.
† Neurodevelopmental consequences may occur in children with hypercalcemia and may improve during treatment.
† Calcimimetics can be used to successfully treat the pathophysiology of NSHPT directly to control serum calcium levels.http://www.edmcasereports.com
Published by Bioscientifica Ltd
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Figure 1
(A) Chest X-ray for patient 1, at 1 month of age, shows an elongated and
narrowed rib cage with irregular rib ends (arrows). The rib cage was also
narrow in an anteroposterior direction (not shown). (B) There are areas of
sclerosis in the distal radius and ulna at 1 month of age (arrow).
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The calcium-sensing receptor (CASR) is a 1078 amino acid
cell surface protein with a large extracellular domain that
tightly regulates calcium homeostasis (1). Under normal
conditions, increasing extracellular calcium concen-
trations activate the CASR, diminishing parathyroid
hormone (PTH) release and augmenting renal calcium
excretion (2). Inactivating CASR gene mutations lead to
variable degrees of hypercalcemia. Heterozygous
mutations usually result in mild hypercalcemia seen in
familial hypocalciuric hypercalcemia (FHH). Homozygous
CASR mutations result in neonatal severe hyperpara-
thyroidism (NSHPT), producing life-threatening hyper-
calcemia and extreme PTH and alkaline phosphatase
elevations in the neonatal period. Patients usually present
in the first weeks of life with failure to thrive, hypotonia,
respiratory distress, and metabolic bone disease. Bone
abnormalities can include undermineralization, rib cage
deformities, subperiosteal erosions, metaphyseal widening
of the long bones, and fractures (1).
Heterozygous CASR gene mutations resulting in the
NSHPT phenotype have also been described (3) (4) (5). The
heterozygous mutation, R185Q, is one such mutation and
in vitro studies have demonstrated the dominant negative
inhibition of the WT CASR by this mutant CASR (4) (6).
Until recently, the only effective therapy for NSHPT
was surgical parathyroidectomy (7). Despite improved
surgical outcomes, this is still a complex procedure in
very young patients (2) (8). Few surgeons have parathyr-
oidectomy experience in infants due to the rarity of the
disorder. The need for medical management of other
PTH-dependent hypercalcemic disorders drove the
development of allosteric CASR agonists, namely cinacal-
cet (9). Three previous case studies have shown the
successful use of cinacalcet, in NSHPT (8) (10) (11). Here
we report the cases of two unrelated patients with de novo
R185Q heterozygous inactivating CASR mutations and
highlight their rapid biochemical and clinical response
to treatment with cinacalcet.Case presentation: case 1
Patient 1 was a term male infant with global hypotonia,
bell-shaped chest, and metaphyseal irregularities (Fig. 1)
that led to an initial clinical diagnosis of Juene’s
syndrome. This is an autosomal recessive skeletal cilio-
pathy causing a short-rib thoracic dysplasia, short-limbed
short stature, and severe thoracic constriction (12).
The Juene’s syndrome phenotype is variable but to ourhttp://www.edmcasereports.comknowledge does not include hypercalcemia (12). He later
presented to endocrine care at age 11 months after
additional review of the radiographs indicated diffuse
osteopenia, short ribs with irregular rib ends, and
metaphyseal sclerosis at the ends of multiple long bones,
suggesting a metabolic bone disease, and biochemical
evaluation revealed hypercalcemia (Table 1).Investigation: case 1
Primary hyperparathyroidism was evident with hypercal-
ciuria, consistent with excessive calcium load filtered
at the glomerulus. Retrospectively, hypercalcemia
(11.7–12.9 mg/dl) had been present on lab testing in the
neonatal period, but had not been investigated until seen
by endocrinology at 11 months of age. At this age he had
gross motor, fine motor and speech delays and dysphagia
requiring gastrostomy tube feedings. There was no family
history of hypercalcemia or bone disease. Both parents
were normocalcemic. Sequencing of the CASR gene
revealed a heterozygous R185Q missense mutation.
Initial therapy included 0.9% saline, phosphate
supplementation, and a low-calcium formula. He had
a transient response to a single dose of pamidronate
(0.5 mg/kg i.v.), but serum calcium rose to 13.8 mg/dl after
only 2 weeks. Therefore, definitive therapy was sought.Treatment: case 1
Cinacalcet, 15 mg orally twice daily (3.7 mg/kg per day),
was begun at 13 months of age based on dosing from the
first published case report (11). The tablets were crushed2
Table 1 Patient biochemistries at NSHPT diagnosis.
Lab Patient 1 values at diagnosis at 11 months Patient 2 values at diagnosis at 1 month Normal range for age
Calcium 13.8 mg/dl 13.3 mg/dl 8.5–10.5
Albumin 3.9 g/dl 3.1 g/dl 3.1–4.2
Alkaline phosphatase 235 U/l 372 U/l 88–351
Phosphorus 4.4 mg/dl 4.4 mg/dl 4.8–8.1
Parathyroid hormone 76 pg/ml 196 pg/ml 10–65
Urine Ca/Cr 2.3 mg/mg !0.08 mg/mg !0.6 (patient 1)
!0.8 (patient 2)
Vitamin D 25 17 ng/ml 30.2 ng/ml 25–80
Vitamin D 1,25 40 pg/ml 230 pg/ml 24–86
Magnesium 3.1 mg/dl 2.4 mg/dl 1.6–2.9
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levels normalized (10.4 mg/dl) within 4 weeks and
phosphorus levels rose to near normal (4.3 mg/dl)
(Fig. 2A). The low-calcium formula was discontinued and
calcium restriction lifted. The cinacalcet dose ranged from
30 to 60 mg/day (2.4–7.4 mg/kg per day) in two to four
divided doses to target serum calcium levels below
12 mg/dl (Fig. 2B). Phosphorus supplementation was
discontinued at 16 months of age. PTH and alkaline
phosphatase levels normalized with only brief elevations
and ranged between 30–78 pg/ml and 209–565 U/l
respectively.14
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Figure 2
(A) Longitudinal calcium (black circles) and phosphorus (open squares)
values during cinacalcet treatment and (B) corresponding cinacalcet dosing
(mg/kg per day). The mg/kg per day dosing is approximate, as dose changes
were made more frequently than weight checks.
http://www.edmcasereports.comOutcome and follow-up: case 1
To date, patient 1 has continued cinacalcet monotherapy
for 32 months without adverse incident. Calcium levels
have remained slightly elevated (10.4–12 mg/dl) except
for one time point when a dose increase was required. PTH
levels have been maintained in the normal range. Our
patient experienced mild nausea and vomiting after one
dose increase, but these well-known side effects of
cinacalcet resolved with a dose decrease. His develop-
mental delays improved slowly and at 3 years of age he no
longer required interventional services. His dysphagia
resolved and his gastrostomy tube was removed 5 months
after starting cinacalcet. His weight (3–10th percentile)
and height (10–25th percentile) steadily increased while
taking cinacalcet. He has not experienced fractures and
does not complain of bone pain.Case presentation: case 2
Patient 2, a term female infant, presented at 26 days of
age with failure of linear growth, poor weight gain, and
cough. A chest X-ray was obtained showing multiple rib
fractures. Subsequently, a skeletal survey revealed diffu-
sely osteopenic bones with coarse trabecular markings,
diffuse symmetric periosteal reactions, and healing lateral
right fourth to ninth and left seventh to ninth rib
fractures (Fig. 3).Investigation: case 2
Laboratory evaluation revealed hyperparathyroidism
(Table 1). There was no family history of hypercalcemia
or bone disease. Both parents were normocalcemic.
Sequencing of the CASR gene revealed a heterozygous
R185Q missense mutation. Infusion of fluids with
0.9% saline, oral phosphorus supplementation, and a3
Figure 3
Chest X-ray for patient 2, at 4 weeks of age, shows generalized osteopenia
and numerous multilevel bony callus formations along several contiguous
ribs bilaterally, suggesting healing fractures (arrows) involving ribs two to
nine on the right and ribs two to seven on the left.
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decreased to 11–12 mg/dl, but the patient had worsening
respiratory distress and was diagnosed with adenovirus.
She required ventilator support for 5 days. Notably,
calcium levels were controlled during this time
(11.4–11.5 mg/dl). Her respiratory distress resolved and
after demonstrating adequate weight gain she was
discharged on only a low-calcium formula and
phosphorus supplementation. She maintained a calcium
level generally below 12 mg/dl but significant PTH and
alkaline phosphatase elevations developed over the next
12 weeks (Fig. 4A and B).
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Figure 4
(A) Longitudinal calcium (black circles) and phosphorus (open squares), (B)
PTH (black circles) and alkaline phosphatase (open squares) values before
and during cinacalcet treatment, and (C) corresponding cinacalcet dosing
(mg/kg per day). The mg/kg per day dosing is approximate as dose changes
were made more frequently than weight checks.Treatment: case 2
Cinacalcet, 6 mg orally daily (2 mg/kg per day), was
initiated at 4 months of age. Our hospital’s pharmacy
made a compounded solution (6 mg/ml) to allow for small
doses. Initial dosing and titration was done in an inpatient
environment to monitor for side effects and obtain
frequent laboratory monitoring. A decrease in her calcium
level from 12.5 to 11.9 mg/dl was noted over 18 h.
Cinacalcet dose titrations normalized her PTH in 11 days
and her serum calcium remained within our goal of
!12 mg/dl during this time (Fig. 4 A, B and C). Alkaline
phosphatase decreased gradually and normalized after 15
weeks of cinacalcet therapy. Our patient remained mildlyhttp://www.edmcasereports.comhypercalcemic (10.5–12.7 mg/dl) and dose increases were
performed for values above 12 mg/dl while targeting a
normal PTH and alkaline phosphatase. She experienced
no symptoms from the intermittent hypercalcemia, and
the highest calcium values were noted after missing
cinacalcet doses. Specific doses ranged between 6 mg
daily and 10 mg three times a day orally (1.68–2.7 mg/kg
per day) over 13 months of therapy.Outcome and follow-up: case 2
She experienced no adverse side effects from cinacalcet,
including hypocalcemia. A renal ultrasound at 1 month of
age (before therapy) demonstrated mild nephrocalcinosis4
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demonstrated healing by radiograph at 4 months of age
and she experienced no further fractures. She had
improved weight gain after reduction in her calcium levels
(w50th percentile for weight and w25th percentile for
length at 4 months), which continued after starting
cinacalcet (w90th percentile for weight and w75th
percentile for length at 12 months). Her development
throughout her first year of life was normal and without
any noted delays.Ta
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We present the successful medical management of
symptomatic hypercalcemia due to NSHPTwith cinacalcet
mono-therapy. Our cases responded similarly to the three
reported cases of NSHPT treated successfully with cina-
calcet and reinforce that medical management without
surgery can successfully control the hypercalcemia and its
sequelae in NSHPT due to the dominant negative
heterozygous R185Q mutation. The rare nature of
NSHPT makes it unlikely that randomized clinical
trials will be feasible, highlighting the value of detailed
case reports.
To date, there have been three published cases of
NSHPT successfully treated with cinacalcet (reviewed in
Table 2) (8) (10) (11). The first, in 2011, was an infant with
the heterozygous R185Q CASR mutation treated with
cinacalcet at 3 weeks of age (11). This patient responded
well with long-term normalization of PTH levels and near
normalization of calcium levels without reported side
effects (11). The second report, in 2012, described a child
with a homozygous CASR mutation treated with cinacal-
cet at 6 years of age with normalization of PTH and near
normalization of calcium levels (8). The third case, in
2014, was a newborn with the heterozygous R185Q
mutation (10). This patient had a similar course and the
authors emphasized that calcium levels may not normal-
ize because of the dominant inhibitor effect of the
abnormal CASR protein (10).
Both of our patients also had continued mild
hypercalcemia with normalization of PTH and
phosphorus levels despite increased cinacalcet doses. We
targeted a calcium level below 12 mg/dl for several
reasons. Levels in this range are less likely to induce
symptoms and patients with FHH have similar levels
without adverse long-term effects.
Our first patient had a bell-shaped chest, a feature that
has been observed in other case reports of patients with a
R185Q CASR mutation (10) (13). He initially received ahttp://www.edmcasereports.com 5
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NSHPT diagnosis. Therefore, NSHPT should be in the
differential of a newborn with a bell-shaped chest,
osteopenia, and periosteal reactions.
Hypercalcemia can cause many devastating symp-
toms, including the developmental delays seen in our first
patient. Importantly, he had marked improvement once
his calcium levels decreased. Our second patient was
treated at a young age and hence did not experience
developmental delays. Both patients gained weight and
height well and experienced no significant adverse side
effects directly from cinacalcet therapy.
Cinacalcet was not initiated immediately at diagnosis
in patient 2 for several reasons: she had initial clinical
and biochemical improvement with low-calcium formula
alone; there were reports that hyperparathyroidism in an
infant with a heterozygous inactivating CASR mutation
born to a normocalcemic mother may improve over time
(11) (14); and a clinical trial investigating cinacalcet use
for hyperparathyroidism in pediatric patients with
chronic kidney disease had just announced a death and
been halted (15). However, evidence of worsening skeletal
turnover necessitated beginning treatment and after
discussion with the parents regarding the risks and
benefits of the alternatives, cinacalcet was chosen and
consent for treatment signed. Although no long-term
pediatric safety analysis is available for cinacalcet, we
propose continued monitoring of calcium, phosphorus,
PTH, and alkaline phosphatase levels to direct dosing and
ongoing intermittent monitoring of kidney function,
urinary calcium, and renal ultrasounds. We plan to
continue therapy indefinitely, as the alternative requires
parathyroid surgery to manage serum calcium. It may,
however, be possible to taper off treatment while
monitoring serum calcium, as our first patient has had a
steady decrease in his dose as he has grown (Fig. 2B).
Despite the above reported successes, in vitro studies
have shown varying effects of cinacalcet in different CASR
mutations, suggesting that cinacalcet may not be effective
in every case. The residual functionality of the CASR
protein and location of the mutation in the trans-
membrane receptor may be important predictors of
success with cinacalcet treatment (16). In accordance,
two cases of NSHPT have been described where cinacalcet
therapy failed (13) (17). These cases had different CASR
mutations from each other, but both resulted in a non-
functional protein due to truncating mutations. A
cataloguing of CASR mutations and their response to
therapy may be a valuable asset in determining treatment
for NSHPT.http://www.edmcasereports.comIn conclusion, we report two cases of NSHPT caused by
a heterozygous inactivating dominant negative CASR
mutation that responded very well to cinacalcet mono-
therapy. Our patients also showed improvements in bone
structure and did not fracture while on cinacalcet therapy.
While the response to cinacalcet will be dictated by
residual function of the CASR protein, we suggest that a
trial of cinacalcet be undertaken in infants and children
with significant hypercalcemia and metabolic bone
disease secondary to CASR mutations.Declaration of interest
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